The role of PI3K in the proliferation and survival of sarcoma is largely unknown; however, we previously reported that ZSTK474, a PI3K inhibitor, showed long-term disease stability in three out of four sarcoma patients enrolled in a Phase 1b clinical trial for cancer patients harboring solid tumors [18, 19]. Here, PIK3CA is linked to cancer.